Oral and Genital Tardive Pain Syndromes
Neurol 44:2115-2119, Ford,B.,et al, 1994
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
NEJM 330:613-622, Lipton,S.A.&Rosenberg,P.A., 1994
Prophylactic Neuroprotection for Cerebral Ischemia
Stroke 25:1075-1080, Fisher,M.,et al, 1994
A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
NEJM 330:585-591, Bensimon,G.,et al, 1994
Evolving Toward Effective Therapy for Acute Ischemic Stroke
JAMA 270:360-364, Fisher,M.&Bogousslavsky,J., 1993
Multiple Sclerosis with Very Late Onset
Neurol 42:1907-1910, Hooge,J.P.&Redekop,W.K., 1992
Pharmacologic Treatment of Childhood Migraine
J Pediatr 120:653-657, Ingarashi,M.,et al, 1992
Clinicopath Conf
Huntington's Diseae, Case2-1992, NEJM 326:117-125992., , 1992
A Follow-Up Study of Isolated Cases of Suspected Huntington's Disease
Ann Neurol 31:293-298, Bateman,D.,et al, 1992
Do NMDA Antagonists Prevent Neuronal Injury? Yes
ARch Neurol 49:418-420, Albers,G.W.,et al, 1992
Do NMDA Antagonists Prevent Neuronal Injury? No
Arch Neurol 49:420-421, Buchan,A.M., 1992
Subarachnoid Haemorrhage
Lancet 339:653-655, Van Gijn,J., 1992
N-Methyl-D-Aspartate Antagonists in the Treatment of Parkinson's Disease
Arch Neurol 48:977-981, Greenamyre,J.T.&O'Brien,C.F., 1991
Migraine-Related Stroke in Childhood
Lancet 337:825-826, , 1991
The Epidemiology of Parkinson's Disease, A Case-Control Study of Young-Onset and Old-Onset Patients
Arch Neurol 48:903-907, Stern,M.,et al, 1991
Does Ageing Aggravate Parkinsonisn Disability?
JNNP 54:780-782, Blin,J.,et al, 1991
Late-Life Migraine
Arch Neurol 48:1174-1177, Aring,C.D., 1991
Tissue Plasminogen Activator Plus Glutamate Antagonist Improves Outcome after Embolic Stroke
Arch Neurol 48:1235-1238, Zivin,J.A.&Mazzarella,V., 1991
The Relationship of Age of Outcome in Myasthenia Gravis
Neurol 40:786-790, Donaldson,D.H.,et al, 1990
Effect of Nimodipine on Cerebral Infarction & Outcome after Subarachnoid Haemorrhage:British Aneurysm Nimodipine Trial
BMJ 298:636-642, Pickard,J.D.,et al, 1989
Effect of Age at Onset on Progression and Mortality in Parkinson's Disease
Neurol 39:1187-1190, Diamond,S.G.,et al, 1989
Risk Factors for Progression in Parkinson's Disease
Neurol 38:1841-1844, Goetz,C.G.,et al, 1988
Hallervorden-Spatz Syndrome:Clinical and Magnetic Resonance Imaging Correlations
Ann Neurol 24:692-694, Sethi,K.D.,et al, 1988
Criteria for an Increased Specificity of MRI Interpretation in Elderly with Suspected Multiple Sclerosis
Neurol 38:1822-1825, Fazekas,F.,et al, 1988
A Comparison of Clinical and Pathological Features of Young-and Old-Onset Parkinson's Disease
Neurol 38:1402-1406, Gibb,W.R.G.&Lees,A.J., 1988
MR Imaging in a Case of Hallervorden-Spatz Disease
J Comput Assist Tomogr 11:1057-1058, Tanfani,G.,et al, 1987
Huntington's Disease, Pathogenesis & Management
NEJM 315:1267-1276, Martin,J.B.&Gusella,J.F., 1986
Late-Life Migraine Accompaniments-Further Experience
Stroke 17:1033-1042, Fisher,C.M., 1986
Hallervorden-Spatz Disease:Cysteine Accumulation & Cysteine Dioxygenase Deficiency in the Globus Palladus
Ann Neurol 18:482-489, Perry,T.L.,et al, 1985
Late-Onset Hallervorden-Spatz Disease Presenting as Familial Parkinsonism
Neurol 35:227-234, Jankovic,J.,et al, 1985
Late-Onset Wilson's Disease with Neurological Involvement in the Absence of Kayser-Fleischer Rings
Ann Neurol 17:411-413, Ross,M.E.,et al, 1985
Parental Transmission in Huntington's Disease
Lancet 1:1100-1102, Went,L.N.,et al, 1984
Neuromyelitis Optica in the Elderly
Arch Neurol 41:670-672, Filley,C.M.,et al, 1984
Multiple Sclerosis After Age 50
Neurol 33:1537-1544, Noseworthy,J.,et al, 1983
Senile-Onset Vocal & Motor Tics
Arch Neurol 40:825-826, Sutula,T.,et al, 1983
Long Latency Between the Onset of Motor & Vocal Tics in Tourette's Syndrome
Ann Neurol 14:693-694, Lang,A.E.,et al, 1983
Maternal Transmission in Huntington's Disease
Lancet 1:208-210, Myers,R.H.,et al, 1983
Juvenile-Onset Dopa-Responsive Dystonia-Until It Isnt
Neurol 104:e213436, Paredes,N.C.,et al, 2025
A 19-Year-Old Woman with Progressive Weakness and Numbness in Her Arms and Legs
Neurol 104:e213495, Alsabah,A-A.,et al, 2025
A 60-Year-Old Man with Weakness and Gait Dysfunction
JAMA Neurol 82:305-306, Jones,F.J.S.,et al, 2025
Calcitonin Gene-Related Peptide-Targeted Therapy in Migraine: Current Role and Future Perspectives
Lancet 405:1014-1026, Versijpt,J.,et al, 2025
Endovascular Therapy for Patients with Low NIHSS Scores and Large Vessel Occlusion in the 6- to 24-Hour Window
Neurol 104:e213442, Marto,J.P.,et al, 2025
Congenital Titinopathy:Comprehensive Characterization of the Most Severe End of the Disease Spectrum
Ann Neurol 97:611-628, Coppens,S.,et al, 2025
Alteplase for Posterior Circulation Ischemic Stropke at 4.5 to 24 Hours
NEJM 392:1288-1296, Yan,S.,et al, 2025
Long-Term Effects of Antidarsagene Autotemcel for Metachromatic Leukodystrophy
NEJM 392:1609-1620, Fumagalli,F.,et al, 2025
Long-Term Consumption of Ultraprocessed Foods and Prodromal Features of Parkinson Disease
Neurol 104:e213562, Wang,P.,et al, 2025
Rapidly Progressive Frontotemporal Dementia with Amytrophic Lateral Sclerosis in an Elderly Female
Cureus doi:10.7759/CUREUS.32182, Sweedan,Y.G.,et al, 2025
Posttransplant Anti-GABAA Receptor Antibody-Associated Autoimmune Encephalitis
Neurol 102:e209245, Togni,C.L.,et al, 2024
IV Thrombolysis in Basilar Artery Occlusion, Outcomes and Comparison with Endovascular Thrombectomy
Neurol 102:e209249, Raty,S.,et al, 2024
Recurrent Rhombencephalitis Associatedwith Anti-GAD65 Antibody
Neurol 102:e208040, Alferes,A.R.,et al, 2024